Most patients with BC have tumors that express estrogen receptor-α (ERα-66kD) and/or progesterone receptor (PR) at diagnosis and therefore are candidates for endocrine treatments to improve clinical outcomes. The gene discussed is ESR1; the disease is breast cancer.